Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

4.5K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.5K
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

155
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
155
Stem Cell Culture01:17

Stem Cell Culture

5.9K
Stem cell research aims to find ways to use stem cells to regenerate and repair cellular damage. Over time, most adult cells undergo the wear and tear of aging and lose their ability to divide and repair themselves. Stem cells do not display a particular morphology or function. Adult stem cells, which exist as a small subset of cells in most tissues, keep dividing and can differentiate into a number of specialized cells generally formed by that tissue. These cells enable the body to renew and...
5.9K
iPS Cell Differentiation01:22

iPS Cell Differentiation

3.0K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
3.0K
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

190
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
190
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

189
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
189

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Management of Tacrolimus-induced thrombotic microangiopathy in a heart transplant recipient: Utilizing novel immunosuppression strategies.

JHLT open·2026
Same author

Proprotein convertase subtilisin/kexin type 9-CC-motif chemokine ligand 2 interactions link lipoprotein(a) composition to intermediate monocyte inflammation in coronary artery disease.

Atherosclerosis plus·2026
Same author

Belatacept as an Emerging Option in Immunosuppression-Induced Thrombotic Microangiopathy After Heart Transplantation.

JACC. Case reports·2026
Same author

Biomarkers and genetic determinants of cardiac sarcoidosis: current status, the unmet needs and future perspectives.

Frontiers in cardiovascular medicine·2026
Same author

Net Prolongation of Life in Advanced Heart Failure: An Intentional Strategy of Durable LVAD Therapy Followed by Heart Transplantation.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation·2026
Same author

Mechanical circulatory support for cardiogenic shock in takotsubo syndrome.

Clinical research in cardiology : official journal of the German Cardiac Society·2026

Related Experiment Video

Updated: Dec 12, 2025

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment
08:24

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment

Published on: May 25, 2020

7.3K

Stem Cell Therapy for Chronic and Advanced Heart Failure.

Gregor Poglajen1,2, Sabina Frljak3, Gregor Zemljič3

  • 1Department of Cardiology, Advanced Heart Failure and Transplantation Center, University Medical Center Ljubljana, Zaloška cesta 7, 1000, Ljubljana, Slovenia. gregor.poglajen@kclj.si.

Current Heart Failure Reports
|August 13, 2020
PubMed
Summary

Cell therapy shows promise for heart failure patients, improving function in reduced ejection fraction and offering encouraging results in preserved ejection fraction and advanced cases. Personalized approaches are key for future treatments.

Keywords:
Advanced heart failureChronic heart failureLVADStem cell therapy

More Related Videos

Isolation, Characterization, and Differentiation of Cardiac Stem Cells from the Adult Mouse Heart
11:45

Isolation, Characterization, and Differentiation of Cardiac Stem Cells from the Adult Mouse Heart

Published on: January 7, 2019

6.9K
In Vitro Differentiation of Human Mesenchymal Stem Cells into Functional Cardiomyocyte-like Cells
09:05

In Vitro Differentiation of Human Mesenchymal Stem Cells into Functional Cardiomyocyte-like Cells

Published on: August 9, 2017

11.3K

Related Experiment Videos

Last Updated: Dec 12, 2025

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment
08:24

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment

Published on: May 25, 2020

7.3K
Isolation, Characterization, and Differentiation of Cardiac Stem Cells from the Adult Mouse Heart
11:45

Isolation, Characterization, and Differentiation of Cardiac Stem Cells from the Adult Mouse Heart

Published on: January 7, 2019

6.9K
In Vitro Differentiation of Human Mesenchymal Stem Cells into Functional Cardiomyocyte-like Cells
09:05

In Vitro Differentiation of Human Mesenchymal Stem Cells into Functional Cardiomyocyte-like Cells

Published on: August 9, 2017

11.3K

Area of Science:

  • Cardiology
  • Regenerative Medicine
  • Cell Therapy

Background:

  • Heart failure, particularly with reduced ejection fraction (HFrEF), remains a significant clinical challenge.
  • Cell therapy is emerging as a potential therapeutic strategy for various heart failure etiologies.
  • Understanding the efficacy across different heart failure phenotypes is crucial.

Purpose of the Study:

  • To review recent advancements in cell therapy for heart failure patients.
  • To cover patients with ischemic (iCMP) and non-ischemic (dCMP) HFrEF.
  • To explore cell therapy in heart failure with preserved ejection fraction (HFpEF) and advanced heart failure with LVAD support.

Main Methods:

  • Review of recent clinical trials and studies on cell therapy in heart failure.
  • Analysis of outcomes in different heart failure patient cohorts.
  • Synthesis of current evidence on cell therapy efficacy and future directions.

Main Results:

  • Cell therapy improved myocardial performance, functional capacity, and neurohumoral activation in HFrEF patients.
  • Initial data in HFpEF suggest benefits in myocardial and diastolic function, exercise capacity, and neurohumoral activation.
  • Cell therapy in advanced heart failure patients with LVAD support showed potential for myocardial reverse remodeling and recovery.

Conclusions:

  • Cell therapy demonstrates promising results across various chronic and advanced heart failure populations.
  • Personalized therapeutic strategies, including optimal cell type, dose, and delivery, are essential for future advancements.
  • Further research is warranted to refine cell therapy protocols for individual patient needs.